103 related articles for article (PubMed ID: 7962467)
21. Inhibition of uterine contractility by progesterone and progesterone metabolites: mediation by progesterone and gamma amino butyric acidA receptor systems.
Putnam CD; Brann DW; Kolbeck RC; Mahesh VB
Biol Reprod; 1991 Aug; 45(2):266-72. PubMed ID: 1664743
[TBL] [Abstract][Full Text] [Related]
22. Molecular properties and preclinical pharmacology of JNJ-1250132, a steroidal progesterone receptor modulator that inhibits binding of the receptor to DNA in vitro.
Allan GF; Palmer E; Musto A; Lai MT; Clancy J; Palmer S
Steroids; 2006 Jul; 71(7):578-84. PubMed ID: 16597452
[TBL] [Abstract][Full Text] [Related]
23. Synthesis of 11beta-(4-dimethylaminophenyl)-17beta-hydroxy-17alpha- (3-methyl-1-butynyl)-4, 9-estradien-3-one and 11beta-(4-acetophenyl)- 17beta-hydroxy-17alpha-(3-methyl-1-butynyl)-4, 9-estradien-3-one: two new analogs of mifepristone (RU-486).
Hazra BG; Basu S; Pore VS; Joshi PL; Pal D; Chakrabarti P
Steroids; 2000 Mar; 65(3):157-62. PubMed ID: 10699595
[TBL] [Abstract][Full Text] [Related]
24. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT.
Jackson TA; Richer JK; Bain DL; Takimoto GS; Tung L; Horwitz KB
Mol Endocrinol; 1997 Jun; 11(6):693-705. PubMed ID: 9171233
[TBL] [Abstract][Full Text] [Related]
25. Clinical uses of antiprogestogens.
Van Look PF; von Hertzen H
Hum Reprod Update; 1995 Jan; 1(1):19-34. PubMed ID: 9080204
[TBL] [Abstract][Full Text] [Related]
26. Parallel synthesis and SAR study of novel oxa-steroids as potent and selective progesterone receptor antagonists.
Kang FA; Guan J; Jain N; Allan G; Linton O; Tannenbaum P; Chen X; Xu J; Zhu P; Gunnet J; Demarest K; Lundeen S; Sui Z
Bioorg Med Chem Lett; 2007 May; 17(9):2531-4. PubMed ID: 17317167
[TBL] [Abstract][Full Text] [Related]
27. RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor.
Bardon S; Vignon F; Chalbos D; Rochefort H
J Clin Endocrinol Metab; 1985 Apr; 60(4):692-7. PubMed ID: 3972969
[TBL] [Abstract][Full Text] [Related]
28. Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues.
Lin VC; Aw SE; Ng EH; Ng EH; Tan MG
Br J Cancer; 2001 Dec; 85(12):1978-86. PubMed ID: 11747343
[TBL] [Abstract][Full Text] [Related]
29. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
[TBL] [Abstract][Full Text] [Related]
30. 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents.
Edwards JP; West SJ; Marschke KB; Mais DE; Gottardis MM; Jones TK
J Med Chem; 1998 Jan; 41(3):303-10. PubMed ID: 9464361
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of 11 beta,13 beta- and 13 beta,16 beta-propano steroids: probes of hormonal activity.
Pitt CG; Rector DH; Cook CE; Wani MC
J Med Chem; 1979 Aug; 22(8):966-70. PubMed ID: 226703
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, antifertility activity, and protein binding affinity of 7(8 leads to 11 alpha)abeo steroids.
Wani MC; Rector DH; White DH; Pitt CG; Kimmel GL
J Med Chem; 1977 Apr; 20(4):547-51. PubMed ID: 850240
[TBL] [Abstract][Full Text] [Related]
33. [The endocrinologic profile of metabolites of the progestin dienogest].
Oettel M; Kaufmann G; Kurischko A
Pharmazie; 1993 Jul; 48(7):541-5. PubMed ID: 8415850
[TBL] [Abstract][Full Text] [Related]
34. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways.
Beck CA; Weigel NL; Moyer ML; Nordeen SK; Edwards DP
Proc Natl Acad Sci U S A; 1993 May; 90(10):4441-5. PubMed ID: 8389450
[TBL] [Abstract][Full Text] [Related]
35. Transactivation of progestin- and estrogen-responsive promoters by 19-nor progestins in African Green Monkey Kidney CV1 cells.
Pasapera AM; Gutiérrez-Sagal R; García-Becerra R; Ulloa-Aguirre A; Savouret JF
Endocrine; 2001 Dec; 16(3):217-25. PubMed ID: 11954666
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and identification of novel oxa-steroids as progesterone receptor antagonists.
Kang FA; Allan G; Guan J; Jain N; Linton O; Tannenbaum P; Xu J; Zhu P; Gunnet J; Chen X; Demarest K; Lundeen S; Sui Z
Bioorg Med Chem Lett; 2007 Feb; 17(4):907-10. PubMed ID: 17169557
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of antiprogestational steroids.
Wiechert R; Neef G
J Steroid Biochem; 1987; 27(4-6):851-8. PubMed ID: 3320563
[TBL] [Abstract][Full Text] [Related]
38. Identification and characterization of novel estrogen receptor-beta-sparing antiprogestins.
Sathya G; Jansen MS; Nagel SC; Cook CE; McDonnell DP
Endocrinology; 2002 Aug; 143(8):3071-82. PubMed ID: 12130573
[TBL] [Abstract][Full Text] [Related]
39. Structural requirements for progestational activity. Synthesis and properties of rac-8alpha,9beta,10alpha,14beta-progesterone.
Solo AJ; Kumar V; Alks V
J Med Chem; 1979 Feb; 22(2):129-33. PubMed ID: 423192
[TBL] [Abstract][Full Text] [Related]
40. Nonsteroidal progestins and antiprogestins related to flutamide.
Dukes M; Furr BJ; Hughes LR; Tucker H; Woodburn JR
Steroids; 2000; 65(10-11):725-31. PubMed ID: 11108883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
